Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
patient starts and 125+ unique prescribers, a U.S. list price of $290,000/year , and the company says it is well funded into 2030. Crinetics received a positive CHMP recommendation for paltusotine, supporting a potential European approval around May and a pragmatic, country-by-country launch approach to preserve pricing optionality. The pipeline is built on novel small molecules targeting GPCRs, led by atumelnant moving into Phase 3 for congenital adrenal hyperplasia with encouraging Cushing's signals, paltusotine entering Phase 3 for carcinoid syndrome, and early programs like CRN09682 and TSH/PTH antagonists. Interested in Crinetics Pharmaceuticals, Inc.? Here are five stocks we like better. Executives from Crinetics Pharmaceuticals (NASDAQ:CRNX) used an investor discussion at TD Cowen's 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched acromegaly drug, outline upcoming regulatory and clinical milestones, and describe how it
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals (CRNX) had its price target lowered by Citizens Jmp from $105.00 to $96.00. They now have a "market outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Crinetics (CRNX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
CRNX
Earnings
- 2/26/26 - Beat
CRNX
Sec Filings
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- CRNX's page on the SEC website